Erasca | Investor Presentation Deck | 56 slides · page 39 of 56
The chart shows a statistically significant (***) improvement in survival for the ERAS-801 group compared to the control and other standard-of-care inhibitors.
Pitch deck · traction · show_traction · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 image 1/1 legend 1/1 paragraph 1/1 title 1/1
Components 5
line illustration legend paragraph headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.